Over-the-counter anti-oxidant therapies for use in multiple sclerosis: A systematic review
Background: Anti-oxidant compounds that are found in over-the-counter (OTC) supplements and foods are gaining interest as treatments for multiple sclerosis (MS). They are widely used by patients, sometimes without a clear evidence base. Objective: We conducted a systematic review of animal and clini...
Gespeichert in:
| Veröffentlicht in: | Multiple Sclerosis Journal 2015-10, Vol.21 (12), p.1485-1495 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1495 |
|---|---|
| container_issue | 12 |
| container_start_page | 1485 |
| container_title | Multiple Sclerosis Journal |
| container_volume | 21 |
| creator | Plemel, Jason R. Juzwik, Camille A. Benson, Curtis A. Monks, Michael Harris, Chelsea Ploughman, Michelle |
| description | Background:
Anti-oxidant compounds that are found in over-the-counter (OTC) supplements and foods are gaining interest as treatments for multiple sclerosis (MS). They are widely used by patients, sometimes without a clear evidence base.
Objective:
We conducted a systematic review of animal and clinical research to determine the evidence for the benefits of OTC anti-oxidants in MS.
Methods:
Using predefined criteria, we searched key databases. Two authors scrutinized all studies against inclusion/exclusion criteria, assessed study risk-of-bias and extracted results.
Results:
Of the 3507 titles, 145 met criteria and included compounds, α(alpha)-lipoic acid (ALA), anti-oxidant vitamins, Ginkgo biloba, quercetin, resveratrol and epigallocatechin-3-gallate (ECGC). The strongest evidence to support OTC anti-oxidants was for compounds EGCG and ALA in animal models; both consistently showed anti-inflammatory/anti-oxidant effects and reduced neurological impairment. Only vitamin E, Ginkgo biloba and ALA were examined for efficacy in pilot clinical trials with either conflicting evidence or evidence of no benefit.
Conclusion:
OTC anti-oxidants EGCG and ALA show the most consistent benefit, however only in preclinical studies. There is no evidence that they alter MS relapses or progression. Future work should focus on testing more of these therapies for clinical efficacy before recommending them to MS patients. |
| doi_str_mv | 10.1177/1352458515601513 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1720452376</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1352458515601513</sage_id><sourcerecordid>2325348581</sourcerecordid><originalsourceid>FETCH-LOGICAL-c477t-1c422e8cdf945491826afb9bac27c4c60efb6487a231ce83e037e94986aada4e3</originalsourceid><addsrcrecordid>eNp1kElLBDEQhYMojtvdkwS8eIlm7aS9ibjBwFz04qVJp6s10ptJ96j_3siMCoKnKnhfvap6CB0yesqY1mdMKC6VUUxllCkmNtAOk1oTmmu6mfokky99hnZjfKGUai3UNprxjJtMU7qDHhdLCGR8BuL6qRshYNuNnvTvvkoNTkKwg4eI6z7gKQL2HW6nZvRDAzi6BkIffTzHFzh-xBFaO3qHAyw9vO2jrdo2EQ7WdQ89XF_dX96S-eLm7vJiTlw6dSTMSc7BuKrOpZI5MzyzdZmX1nHtpMso1GUmjbZcMAdGABUacpmbzNrKShB76GTlO4T-dYI4Fq2PDprGdtBPsWCaU6m40FlCj_-gL_0UunRdwQVXQhplWKLoinLpuRigLobgWxs-CkaLr9yLv7mnkaO18VS2UP0MfAedALICon2C363_Gn4CwEKKGg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2325348581</pqid></control><display><type>article</type><title>Over-the-counter anti-oxidant therapies for use in multiple sclerosis: A systematic review</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Plemel, Jason R. ; Juzwik, Camille A. ; Benson, Curtis A. ; Monks, Michael ; Harris, Chelsea ; Ploughman, Michelle</creator><creatorcontrib>Plemel, Jason R. ; Juzwik, Camille A. ; Benson, Curtis A. ; Monks, Michael ; Harris, Chelsea ; Ploughman, Michelle</creatorcontrib><description>Background:
Anti-oxidant compounds that are found in over-the-counter (OTC) supplements and foods are gaining interest as treatments for multiple sclerosis (MS). They are widely used by patients, sometimes without a clear evidence base.
Objective:
We conducted a systematic review of animal and clinical research to determine the evidence for the benefits of OTC anti-oxidants in MS.
Methods:
Using predefined criteria, we searched key databases. Two authors scrutinized all studies against inclusion/exclusion criteria, assessed study risk-of-bias and extracted results.
Results:
Of the 3507 titles, 145 met criteria and included compounds, α(alpha)-lipoic acid (ALA), anti-oxidant vitamins, Ginkgo biloba, quercetin, resveratrol and epigallocatechin-3-gallate (ECGC). The strongest evidence to support OTC anti-oxidants was for compounds EGCG and ALA in animal models; both consistently showed anti-inflammatory/anti-oxidant effects and reduced neurological impairment. Only vitamin E, Ginkgo biloba and ALA were examined for efficacy in pilot clinical trials with either conflicting evidence or evidence of no benefit.
Conclusion:
OTC anti-oxidants EGCG and ALA show the most consistent benefit, however only in preclinical studies. There is no evidence that they alter MS relapses or progression. Future work should focus on testing more of these therapies for clinical efficacy before recommending them to MS patients.</description><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1177/1352458515601513</identifier><identifier>PMID: 26286700</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Animal models ; Animals ; Antioxidants - pharmacology ; Bias ; Bioavailability ; Blood-brain barrier ; Brain research ; Catechin - analogs & derivatives ; Catechin - pharmacology ; Clinical trials ; Dietary supplements ; Epigallocatechin gallate ; Fatty acids ; Ginkgo biloba ; Humans ; Inflammation ; Lipoic acid ; Multiple sclerosis ; Multiple Sclerosis - drug therapy ; Nervous system ; Neurological complications ; Nonprescription Drugs - pharmacology ; Oxidants ; Oxidative stress ; Pathology ; Polyamines ; Polyphenols ; Quercetin ; Quercetin - pharmacology ; Research methodology ; Researchers ; Resveratrol ; Stilbenes - pharmacology ; Thioctic Acid - pharmacology ; Vitamin C ; Vitamin E ; Vitamins</subject><ispartof>Multiple Sclerosis Journal, 2015-10, Vol.21 (12), p.1485-1495</ispartof><rights>The Author(s), 2015</rights><rights>The Author(s), 2015.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c477t-1c422e8cdf945491826afb9bac27c4c60efb6487a231ce83e037e94986aada4e3</citedby><cites>FETCH-LOGICAL-c477t-1c422e8cdf945491826afb9bac27c4c60efb6487a231ce83e037e94986aada4e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1352458515601513$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1352458515601513$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>313,314,780,784,792,21810,27913,27915,27916,43612,43613</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26286700$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Plemel, Jason R.</creatorcontrib><creatorcontrib>Juzwik, Camille A.</creatorcontrib><creatorcontrib>Benson, Curtis A.</creatorcontrib><creatorcontrib>Monks, Michael</creatorcontrib><creatorcontrib>Harris, Chelsea</creatorcontrib><creatorcontrib>Ploughman, Michelle</creatorcontrib><title>Over-the-counter anti-oxidant therapies for use in multiple sclerosis: A systematic review</title><title>Multiple Sclerosis Journal</title><addtitle>Mult Scler</addtitle><description>Background:
Anti-oxidant compounds that are found in over-the-counter (OTC) supplements and foods are gaining interest as treatments for multiple sclerosis (MS). They are widely used by patients, sometimes without a clear evidence base.
Objective:
We conducted a systematic review of animal and clinical research to determine the evidence for the benefits of OTC anti-oxidants in MS.
Methods:
Using predefined criteria, we searched key databases. Two authors scrutinized all studies against inclusion/exclusion criteria, assessed study risk-of-bias and extracted results.
Results:
Of the 3507 titles, 145 met criteria and included compounds, α(alpha)-lipoic acid (ALA), anti-oxidant vitamins, Ginkgo biloba, quercetin, resveratrol and epigallocatechin-3-gallate (ECGC). The strongest evidence to support OTC anti-oxidants was for compounds EGCG and ALA in animal models; both consistently showed anti-inflammatory/anti-oxidant effects and reduced neurological impairment. Only vitamin E, Ginkgo biloba and ALA were examined for efficacy in pilot clinical trials with either conflicting evidence or evidence of no benefit.
Conclusion:
OTC anti-oxidants EGCG and ALA show the most consistent benefit, however only in preclinical studies. There is no evidence that they alter MS relapses or progression. Future work should focus on testing more of these therapies for clinical efficacy before recommending them to MS patients.</description><subject>Animal models</subject><subject>Animals</subject><subject>Antioxidants - pharmacology</subject><subject>Bias</subject><subject>Bioavailability</subject><subject>Blood-brain barrier</subject><subject>Brain research</subject><subject>Catechin - analogs & derivatives</subject><subject>Catechin - pharmacology</subject><subject>Clinical trials</subject><subject>Dietary supplements</subject><subject>Epigallocatechin gallate</subject><subject>Fatty acids</subject><subject>Ginkgo biloba</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Lipoic acid</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Nervous system</subject><subject>Neurological complications</subject><subject>Nonprescription Drugs - pharmacology</subject><subject>Oxidants</subject><subject>Oxidative stress</subject><subject>Pathology</subject><subject>Polyamines</subject><subject>Polyphenols</subject><subject>Quercetin</subject><subject>Quercetin - pharmacology</subject><subject>Research methodology</subject><subject>Researchers</subject><subject>Resveratrol</subject><subject>Stilbenes - pharmacology</subject><subject>Thioctic Acid - pharmacology</subject><subject>Vitamin C</subject><subject>Vitamin E</subject><subject>Vitamins</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kElLBDEQhYMojtvdkwS8eIlm7aS9ibjBwFz04qVJp6s10ptJ96j_3siMCoKnKnhfvap6CB0yesqY1mdMKC6VUUxllCkmNtAOk1oTmmu6mfokky99hnZjfKGUai3UNprxjJtMU7qDHhdLCGR8BuL6qRshYNuNnvTvvkoNTkKwg4eI6z7gKQL2HW6nZvRDAzi6BkIffTzHFzh-xBFaO3qHAyw9vO2jrdo2EQ7WdQ89XF_dX96S-eLm7vJiTlw6dSTMSc7BuKrOpZI5MzyzdZmX1nHtpMso1GUmjbZcMAdGABUacpmbzNrKShB76GTlO4T-dYI4Fq2PDprGdtBPsWCaU6m40FlCj_-gL_0UunRdwQVXQhplWKLoinLpuRigLobgWxs-CkaLr9yLv7mnkaO18VS2UP0MfAedALICon2C363_Gn4CwEKKGg</recordid><startdate>201510</startdate><enddate>201510</enddate><creator>Plemel, Jason R.</creator><creator>Juzwik, Camille A.</creator><creator>Benson, Curtis A.</creator><creator>Monks, Michael</creator><creator>Harris, Chelsea</creator><creator>Ploughman, Michelle</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>201510</creationdate><title>Over-the-counter anti-oxidant therapies for use in multiple sclerosis: A systematic review</title><author>Plemel, Jason R. ; Juzwik, Camille A. ; Benson, Curtis A. ; Monks, Michael ; Harris, Chelsea ; Ploughman, Michelle</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c477t-1c422e8cdf945491826afb9bac27c4c60efb6487a231ce83e037e94986aada4e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Animal models</topic><topic>Animals</topic><topic>Antioxidants - pharmacology</topic><topic>Bias</topic><topic>Bioavailability</topic><topic>Blood-brain barrier</topic><topic>Brain research</topic><topic>Catechin - analogs & derivatives</topic><topic>Catechin - pharmacology</topic><topic>Clinical trials</topic><topic>Dietary supplements</topic><topic>Epigallocatechin gallate</topic><topic>Fatty acids</topic><topic>Ginkgo biloba</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Lipoic acid</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Nervous system</topic><topic>Neurological complications</topic><topic>Nonprescription Drugs - pharmacology</topic><topic>Oxidants</topic><topic>Oxidative stress</topic><topic>Pathology</topic><topic>Polyamines</topic><topic>Polyphenols</topic><topic>Quercetin</topic><topic>Quercetin - pharmacology</topic><topic>Research methodology</topic><topic>Researchers</topic><topic>Resveratrol</topic><topic>Stilbenes - pharmacology</topic><topic>Thioctic Acid - pharmacology</topic><topic>Vitamin C</topic><topic>Vitamin E</topic><topic>Vitamins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Plemel, Jason R.</creatorcontrib><creatorcontrib>Juzwik, Camille A.</creatorcontrib><creatorcontrib>Benson, Curtis A.</creatorcontrib><creatorcontrib>Monks, Michael</creatorcontrib><creatorcontrib>Harris, Chelsea</creatorcontrib><creatorcontrib>Ploughman, Michelle</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Multiple Sclerosis Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Plemel, Jason R.</au><au>Juzwik, Camille A.</au><au>Benson, Curtis A.</au><au>Monks, Michael</au><au>Harris, Chelsea</au><au>Ploughman, Michelle</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Over-the-counter anti-oxidant therapies for use in multiple sclerosis: A systematic review</atitle><jtitle>Multiple Sclerosis Journal</jtitle><addtitle>Mult Scler</addtitle><date>2015-10</date><risdate>2015</risdate><volume>21</volume><issue>12</issue><spage>1485</spage><epage>1495</epage><pages>1485-1495</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><abstract>Background:
Anti-oxidant compounds that are found in over-the-counter (OTC) supplements and foods are gaining interest as treatments for multiple sclerosis (MS). They are widely used by patients, sometimes without a clear evidence base.
Objective:
We conducted a systematic review of animal and clinical research to determine the evidence for the benefits of OTC anti-oxidants in MS.
Methods:
Using predefined criteria, we searched key databases. Two authors scrutinized all studies against inclusion/exclusion criteria, assessed study risk-of-bias and extracted results.
Results:
Of the 3507 titles, 145 met criteria and included compounds, α(alpha)-lipoic acid (ALA), anti-oxidant vitamins, Ginkgo biloba, quercetin, resveratrol and epigallocatechin-3-gallate (ECGC). The strongest evidence to support OTC anti-oxidants was for compounds EGCG and ALA in animal models; both consistently showed anti-inflammatory/anti-oxidant effects and reduced neurological impairment. Only vitamin E, Ginkgo biloba and ALA were examined for efficacy in pilot clinical trials with either conflicting evidence or evidence of no benefit.
Conclusion:
OTC anti-oxidants EGCG and ALA show the most consistent benefit, however only in preclinical studies. There is no evidence that they alter MS relapses or progression. Future work should focus on testing more of these therapies for clinical efficacy before recommending them to MS patients.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>26286700</pmid><doi>10.1177/1352458515601513</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-4585 |
| ispartof | Multiple Sclerosis Journal, 2015-10, Vol.21 (12), p.1485-1495 |
| issn | 1352-4585 1477-0970 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1720452376 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Animal models Animals Antioxidants - pharmacology Bias Bioavailability Blood-brain barrier Brain research Catechin - analogs & derivatives Catechin - pharmacology Clinical trials Dietary supplements Epigallocatechin gallate Fatty acids Ginkgo biloba Humans Inflammation Lipoic acid Multiple sclerosis Multiple Sclerosis - drug therapy Nervous system Neurological complications Nonprescription Drugs - pharmacology Oxidants Oxidative stress Pathology Polyamines Polyphenols Quercetin Quercetin - pharmacology Research methodology Researchers Resveratrol Stilbenes - pharmacology Thioctic Acid - pharmacology Vitamin C Vitamin E Vitamins |
| title | Over-the-counter anti-oxidant therapies for use in multiple sclerosis: A systematic review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T02%3A27%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Over-the-counter%20anti-oxidant%20therapies%20for%20use%20in%20multiple%20sclerosis:%20A%20systematic%20review&rft.jtitle=Multiple%20Sclerosis%20Journal&rft.au=Plemel,%20Jason%20R.&rft.date=2015-10&rft.volume=21&rft.issue=12&rft.spage=1485&rft.epage=1495&rft.pages=1485-1495&rft.issn=1352-4585&rft.eissn=1477-0970&rft_id=info:doi/10.1177/1352458515601513&rft_dat=%3Cproquest_cross%3E2325348581%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2325348581&rft_id=info:pmid/26286700&rft_sage_id=10.1177_1352458515601513&rfr_iscdi=true |